1. Zohair A. Al Aseri MD, FRCPC EM & CCM
Acetaminophen
Zohair A. Al Aseri MD, FRCPC EM & CCM
Zohair Al Aseri MD,FRCPC EM & CCM

2. Acetaminophen PERSPECTIVE
Acetaminophen may be found as an isolated product or in combination medications
Zohair Al Aseri MD,FRCPC EM & CCM

3. PRINCIPLES OF DISEASE
Acetaminophen is absorbed rapidly, with peak plasma concentrations generally occurring within 1 hour and complete absorption within 4 hours.
Zohair Al Aseri MD,FRCPC EM & CCM

4. PRINCIPLES OF DISEASE metabolized by conjugation with
glucuronide (40–67%) and
sulfate (20–46%) into nontoxic metabolites that are excreted in the urine.
A small percentage (<5%) is oxidized to a highly cytotoxic metabolic intermediary, N- acetyl-p-benzoquinonimine (NAPQI).
Zohair Al Aseri MD,FRCPC EM & CCM

5. Acetaminophen (APAP) metabolism and N-acetylcysteine (NAC) mechanisms of action. NAC1 enhances sulfation; NAC2 serves as a glutathione (GSH) precursor; NAC3 is a GSH substitute; NAC4 may reduce systemic toxicity. NAPQI, N-acetyl-p-benzoquinonimine. (Modified from Smilkstein MJ: Acetaminophen. In Goldfrank LR, et al (eds): Goldfrank's Toxological Emergencies, 6th ed, Stamford, Conn, Appleton & Lange, 1998, p 547.)
Zohair Al Aseri MD,FRCPC EM & CCM

6. PRINCIPLES OF DISEASE
The principal therapy for acetaminophen toxicity is N-acetylcysteine (NAC) via two separate mechanisms:
NAC serves as a glutathione precursor and a sulfur-containing glutathione substitute, thereby detoxifying NAPQI and avoiding subsequent hepatotoxicity.
NAC may decrease NAPQI formation by enhancing acetaminophen conjugation with sulfate to nontoxic metabolites.
Zohair Al Aseri MD,FRCPC EM & CCM

7. CLINICAL FEATURES
Hepatic injury, which can progress to hepatic failure and renal failure.
Early, patients may be asymptomatic or have mild nonspecific symptoms
(e.g., nausea, vomiting, anorexia, malaise, diaphoresis)
Zohair Al Aseri MD,FRCPC EM & CCM

8. Time Course and Clinical Stages of Acetaminophen Toxicity
Zohair Al Aseri MD,FRCPC EM & CCM

9. CLINICAL FEATURES
Liver injury becomes evident after a period of 8 to 36 hours as an elevation in aspartate aminotransferase (AST).
Once liver injury has begun, patients may develop right upper quadrant (RUQ) pain or tenderness, vomiting, and jaundice.
AST concentrations continue to rise and usually peak in 2 to 4 days, corresponding to maximal liver injury.
Zohair Al Aseri MD,FRCPC EM & CCM

10. CLINICAL FEATURES
Alanine aminotransferase (ALT), prothrombin time (PT), and bilirubin typically begin to rise and peak shortly after AST values.
In severe toxicity, AST, ALT, and the PT may all be elevated within 24 hours.
Zohair Al Aseri MD,FRCPC EM & CCM

11. CLINICAL FEATURES
patients may develop signs and symptoms fulminant liver failure, including metabolic acidosis, coagulopathy, and hepatic encephalopathy
Zohair Al Aseri MD,FRCPC EM & CCM

12. Risk Assessment with Acute Acetaminophen Ingestion
More than 150 mg/kg in an acute ingestion must be consumed before significant liver toxicity is evident
A serum acetaminophen concentration may be considered in all intentional overdoses
Zohair Al Aseri MD,FRCPC EM & CCM

13. Risk Assessment with Acute Acetaminophen Ingestion
Establish a time of ingestion.
Determine a serum acetaminophen concentration 4 hours postingestion, or as soon as possible after 4 hours.
Measurement of serum acetaminophen concentration prior to 4 hs not necessary.
The serum acetaminophen concentration and the time of ingestion determine the need for antidotal therapy by plotting the serum acetaminophen concentration against the time since ingestion on the treatment Rumack- Matthew nomogram
Zohair Al Aseri MD,FRCPC EM & CCM

14. Treatment nomogram for acute overdose
Treatment nomogram for acute overdose. The lower treatment line should be used for treatment decisions. (Modified from Rumack BH, Matthew H: Acetaminophen poisoning and toxicity. Pediatrics 55:871, 1975.)
Zohair Al Aseri MD,FRCPC EM & CCM

15. Risk Assessment with Acute Acetaminophen Ingestion
If the serum acetaminophen concentration is on or above the treatment line (that starts at 150  g/L at 4 hr and decreases to 4.7  g/L at 24 hr), then antidotal treatment with NAC should be initiated immediately.
Zohair Al Aseri MD,FRCPC EM & CCM

16. Risk Assessment with Acute Acetaminophen Ingestion
If the serum acetaminophen concentration is below the treatment line and the worst case scenario has been taken for the time of ingestion, then the patient requires no antidotal therapy.
Use of the treatment line is a highly sensitive approach and may be used for all acute ingestions.
Zohair Al Aseri MD,FRCPC EM & CCM

17. Risk Assessment with Acute Acetaminophen Ingestion
Fortunately, there is little need to treat patients prior to 6 to 8 hours after ingestion, as patients treated with NAC up to 6 hours after ingestion have no increased risk of hepatotoxicity regardless of their serum acetaminophen concentration.
Zohair Al Aseri MD,FRCPC EM & CCM

18. Risk Assessment with Acute Acetaminophen Ingestion
Risk of hepatotoxicity does not significantly increase unless NAC is delayed for 8 hours or longer after ingestion.
For patients at risk whose serum acetaminophen concentration cannot be obtained prior to 6 to 8 hours after ingestion, a loading dose of NAC should be considered.
Zohair Al Aseri MD,FRCPC EM & CCM

19. MANAGEMENT Mainstays of management are Supportive care
NAC therapy when indicated
Zohair Al Aseri MD,FRCPC EM & CCM

20. Limiting Gastrointestinal Absorption
MANAGEMENT
Limiting Gastrointestinal Absorption
Gastric emptying by lavage is not indicated because of the very rapid absorption of acetaminophen and the availability of an effective antidote.
Zohair Al Aseri MD,FRCPC EM & CCM

21. MANAGEMENT Activated charcoal (AC)
no evidence that administration of AC translates into improved clinical outcomes.
Zohair Al Aseri MD,FRCPC EM & CCM

22. MANAGEMENT N-Acetylcysteine
When indicated, NAC should be administered as early as possible.
Delay of administration of NAC longer than 6 to 8 hours after ingestion increases the risk of hepatotoxicity.
Zohair Al Aseri MD,FRCPC EM & CCM

23. Zohair Al Aseri MD,FRCPC EM & CCM